Conditions: Multiple Myeloma
Keywords: Myeloma Multiple Myeloma Relapsed Multiple Myeloma Relapsed and Refractory Multiple Myeloma Refractory Myeloma Resistant Multiple Myeloma Treatment-resistant Multiple Myeloma Pomalidomide Lenalidomide-resistant Bortezomib-resistant Companion
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 74
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the efficacy and safety of pomalidomide monotherapy in subjects with refractory or relapsed and refractory multiple myeloma who were enrolled in study CC-4047-MM-003 (NCT01311687) and discontinued treatment with high-dose dexamethasone due to disease progression.

Detailed description:

Arms:
arm 1: Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity

Interventions: intervention 1: pomalidomide
Intervention descriptions: intervention 1: Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity

Protocol document: